David F Penson1, June M Chan. 1. Departments of Urology and Preventive Medicine, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA 90089, USA. penson@usc.edu
Abstract
PURPOSE: We quantified the burden of prostate cancer in the United States by identifying trends in incidence, disease presentation, survival rates and use of health care resources, and by estimating the economic impact of the disease. MATERIALS AND METHODS: The analytic methods used to generate these results were described previously. RESULTS: Age adjusted prostate cancer incidence rates peaked in 1992 at 237/100,000 men, decreased in 1995 and then increased at approximately 1.7% yearly through 2000, when the rate was 180/100,000. Marked stage migration and an improvement in 5-year overall survival were also noted. Age adjusted inpatient hospitalizations for prostate cancer decreased in the 1990s from 729/100,000 population in 1992 to 309/100,000 in 2001. Considerable ethnic and regional variation was noted. During the same period age adjusted radical prostatectomy rates varied from 128/100,000 men in 1994 to 108/100,000 in 2000. Surgery rates decreased in older men, while they increased in younger men. Outpatient physician office visits also varied in the 1990s with ethnic and regional variation again noted. Finally, the total medical expenditure for prostate cancer treatment was $1.3 billion in 2000, which represents a 30% increase over the total expenditure for 1994. CONCLUSIONS: The burden of prostate cancer in the United States is considerable and it appears to have markedly increased in the prostate specific antigen era. Further research is needed to determine if we are using our limited health care resources appropriately for the diagnosis and treatment of this common malignancy.
PURPOSE: We quantified the burden of prostate cancer in the United States by identifying trends in incidence, disease presentation, survival rates and use of health care resources, and by estimating the economic impact of the disease. MATERIALS AND METHODS: The analytic methods used to generate these results were described previously. RESULTS: Age adjusted prostate cancer incidence rates peaked in 1992 at 237/100,000 men, decreased in 1995 and then increased at approximately 1.7% yearly through 2000, when the rate was 180/100,000. Marked stage migration and an improvement in 5-year overall survival were also noted. Age adjusted inpatient hospitalizations for prostate cancer decreased in the 1990s from 729/100,000 population in 1992 to 309/100,000 in 2001. Considerable ethnic and regional variation was noted. During the same period age adjusted radical prostatectomy rates varied from 128/100,000 men in 1994 to 108/100,000 in 2000. Surgery rates decreased in older men, while they increased in younger men. Outpatient physician office visits also varied in the 1990s with ethnic and regional variation again noted. Finally, the total medical expenditure for prostate cancer treatment was $1.3 billion in 2000, which represents a 30% increase over the total expenditure for 1994. CONCLUSIONS: The burden of prostate cancer in the United States is considerable and it appears to have markedly increased in the prostate specific antigen era. Further research is needed to determine if we are using our limited health care resources appropriately for the diagnosis and treatment of this common malignancy.
Authors: T N Showalter; K A Foley; E Jutkowitz; C D Lallas; E J Trabulsi; L G Gomella; A P Dicker; L T Pizzi Journal: Ann Oncol Date: 2011-06-09 Impact factor: 32.976
Authors: Timothy N Showalter; Nitin Ohri; Kristopher G Teti; Kathleen A Foley; Scott W Keith; Edouard J Trabulsi; Costas D Lallas; Adam P Dicker; Jean Hoffman-Censits; Laura T Pizzi; Leonard G Gomella Journal: Int J Radiat Oncol Biol Phys Date: 2011-05-24 Impact factor: 7.038
Authors: Bruce J Trock; Misop Han; Stephen J Freedland; Elizabeth B Humphreys; Theodore L DeWeese; Alan W Partin; Patrick C Walsh Journal: JAMA Date: 2008-06-18 Impact factor: 56.272
Authors: Grant Chavin; Yuri Sheinin; Paul L Crispen; Stephen A Boorjian; Timothy J Roth; Laureano Rangel; Michael L Blute; Thomas J Sebo; Don J Tindall; Eugene D Kwon; R Jeffrey Karnes Journal: Clin Cancer Res Date: 2009-03-10 Impact factor: 12.531
Authors: Julia H Hayes; Daniel A Ollendorf; Steven D Pearson; Michael J Barry; Philip W Kantoff; Pablo A Lee; Pamela M McMahon Journal: Ann Intern Med Date: 2013-06-18 Impact factor: 25.391
Authors: Simon M Collin; Richard M Martin; Chris Metcalfe; David Gunnell; Peter C Albertsen; David Neal; Freddie Hamdy; Peter Stephens; J Athene Lane; Rollo Moore; Jenny Donovan Journal: Lancet Oncol Date: 2008-04-16 Impact factor: 41.316